Arbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026

Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the best biotech penny stocks to buy in 2026. On March 23, Arbutus Biopharma concluded 2025 in a robust financial position, reporting $91.5 million in cash, cash equivalents, and marketable securities as of December 31. The company narrowed its annual net loss to $33.5 million ($0.17 per share), compared to $69.9 million in the previous year. This improvement was driven by a disciplined restructuring that reduced R&D expenses by ~$29 million and shifted the corporate focus toward its leading clinical programs, imdusiran and AB-101.

Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran

disease-4392163_1920

A major corporate milestone was reached on March 3, when Arbutus and its partner Genevant Sciences entered into a $2.25 billion global settlement with Moderna. The agreement resolves long-standing patent infringement litigation regarding lipid nanoparticle/LNP delivery technology. Arbutus is set to receive 20% of a $950 million upfront payment in July, after litigation costs, with an additional $1.3 billion contingent on future appellate rulings. Due to this substantial capital influx, management is currently evaluating a return of capital to its shareholders in Q3 2026.

On the clinical front, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported that two additional patients in Phase 2a trials for imdusiran achieved a functional cure for chronic hepatitis B, bringing the total to ten patients to date. The company also recognized revenue from a milestone payment under its LNP license with Alnylam for a hepatocellular carcinoma treatment, further validating its proprietary delivery platform.

Arbutus Biopharma Corporation (NASDAQ:ABUS) develops therapies targeting infectious diseases, including chronic hepatitis B.

While we acknowledge the risk and potential of ABUS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABUS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.